anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study participants who have received first-line treatment for follicular lymphoma and are in complete remission will have blood collected for cfDNA testing. In the retrospective cohort, MSKCC patients with CRs lasting ≥10 years after induction therapy will be studied. Initial tumor tissue (if available) will be collected to examine the status of s cfDNA in patients with long-term remissions. Blood samples will be collected once, if the patient has interesting results (e.g. positive cfDNA sample despite CR on imaging, etc.) then additional blood samples may be taken during follow up visits.
The invention relates to the technical field of traditional Chinese medicines and provides a traditional Chinese medicine composition for preventing tuberculosis according to the tuberculosis understanding mechanism of the traditional Chinese medicine. The traditional Chinese medicine composition is prepared from 2-4 parts by weight of polygala root, 4-8 parts by weight of a bamboo juice, 5-7 parts by weight of radix asteris, 3-5 parts by weight of reddish orange, 10-15 parts of raw coix seeds and 4-8 parts of pinellia ternate. The traditional Chinese medicine composition is decocted by water and the decoction is taken twice every day. One treatment course comprises 15 days. The traditional Chinese medicine composition utilizes easily available raw materials, has good effects, and has no side effect. Through use in hundreds of cases of tuberculosis patients, the statistics result shows that the traditional Chinese medicine composition has an effective rate of 97.5% or more.
FIELD: medicine, pulmonology, allergology. SUBSTANCE: invention relates to treatment of patient suffering with antigen-induced asthma and for decrease of hyperreactivity of respiratory tracts. Method involves intratracheal administration to patient a pharmaceutical composition containing from 0.05 to 1.0 mg of ultralow-molecular heparins with average molecular mass 3 000 Da or less/kg of weight of patient body in each dose. Also, invention relates to the developed pharmaceutical inhalation compositions for their use in the novel method of treatment. Method provides bronchoconstriction arresting and decrease of complications treatment. EFFECT: enhanced effectiveness of treatment. 34 cl, 11 dwg, 7 tbl
ABSTRACT OF THE DISCLOSURE         This invention relates to a pharmaceutical preparation useful for the treatment of infections and diseases which include, for example, conditions such as nasal inflammation, appendicitis, gastritis, enteritis, alveolar brennorrhea, pudendal lacerations and hemorrhoids.  The preparation comprises a single or multiple strain of Lactobacillus as the active ingredient which are grown by the addition of a promoter to a medium which otherwise would not sustain such growth.  The promoters include odoriferous S-compounds, odoriferous N-compounds and lower fatty acids or combinations thereof.  The strains of this invention are non-pathogenic and capable of antibiotic production.  They effectively survive in the growth competition with pathogenic bacteria and can denature selected metabolites, thereby reducing inflammation and swelling in infected areas.  The therapeutic effects of these preparations are markedly improved over those of the prior art.
Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.
BACKGROUND: HPV-independent cervical cancers (HPV-ind CCs) are uncommon with worse prognosis and poorly understood. This study investigated the molecular characteristics of HPV-ind CCs, aiming to explore new strategies for HPV-ind CCs.
METHODS: HPV status of 1010 cervical cancer patients were detected by RT-PCR, PCR and RNA-sequencing (RNA-seq). Whole exome sequencing (WES) and RNA-seq were performed in identified HPV-ind CCs. The efficacy of PI3Kα inhibitor BYL719 in HPV-ind CCs was evaluated in cell lines, patient-derived organoids (PDOs) and patient-derived xenografts (PDXs).
RESULTS: Twenty-five CCs were identified as HPV-ind, which were more common seen in older, adenocarcinoma patients and exhibited poorer prognosis as well as higher tumor mutation burden compared to HPV-associated CCs. HPV-ind CCs were featured with highly activated PI3K/AKT signaling pathway, particularly, PIK3CA being the most predominant genomic alteration (36%). BYL719 demonstrated superior tumor suppression in vitro and in vivo. Furthermore, HPV-ind CCs were classified into two subtypes according to distinct prognosis by gene expression profiles, the metabolism subtype and immune subtype.
CONCLUSIONS: This study reveals the prevalence, clinicopathology, and molecular features of HPV-ind CCs and emphasizes the importance of PIK3CA mutations and PI3K pathway activation in tumorigenesis, which suggests the potential significance of PI3Kα inhibitors in HPV-ind CC patients.
Despite data from clinical trials showing an increased risk of breast cancer and lack of overall benefit for primary prevention with hormone therapy (HT), there is still significant usage of HT by clinicians and women for treatment of moderate-to-severe systemic menopausal symptoms. Due to the possible increased risks with these preparations, current clinical recommendations advocate utilizing the lowest dose for the shortest possible duration, but average duration is often for 2-4 years. However, the effects of commonly used low-dose HT regimens on breast density and breast cancer risk are unknown. Recent data from intervention trials support the long standing hypothesis that hormonal effects on breast cancer risk are mediated through breast density. The Kronos Early Estrogen Prevention Study (KEEPS) is an ongoing, already- funded randomized clinical trial with a primary goal of examining the effects of 4 years of low- dose transdermal versus oral estrogen combined with cyclic micronized progesterone on progression of subclinical atherosclerosis in recently menopausal women. The proposed ancillary study will efficiently examine the effects of randomized low-dose HT on key breast cancer surrogate endpoints: mammographic density and rates of abnormal mammograms. In the parent KEEPS study, a total of 720 women were randomized to oral conjugated equine estrogens (0.45 mg/d), transdermal 17-beta estradiol (50 mcg/d), or placebo, with cyclic micronized progesterone (200 mg for 12 days) for active hormonal therapy groups. All participants were required to have mammography prior to study entry as well as yearly during follow-up; blood samples also were collected at these time points. Randomization was completed in 2008. In this ancillary study, we aimed to collect mammograms from eligible women consenting to be part of the ancillary study(n=517) from baseline, year 1 and year 3 will be obtained and processed centrally to calculate mammographic density. The investigators will determine if these two low-dose HT regimens are associated with change in mammographic density. The investigators will also examine if baseline mammographic density or circulating biomarkers including estradiol, estrone, and estrone sulfate, modify or mediate changes in breast density with HT. In addition, the effects of hormonal regimens on the rates of abnormal mammogram and biopsy will be determined. By determining the effects of low-dose combined HT on the breast, the proposed study will add timely and important information about the estimated balance of risks and benefits associated with low-dose HT and will help guide future research.
The control group consists of basic core exercises which include the activation of transversusabdominins and multifidus muscles and progressive strengethening of these muscles in all positions using swiss balls and floor mats. All exercises were done for at least 3 sets of 15 repetitions to build proper core stability.
Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell displaying a MDR phenotype. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V H  and V L  domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
Obesity is a global health concern associated with an increased risk of cardio-metabolic diseases and reduced overall health. Exercise is a proven modality for managing obesity, with current focus of researches on identifying more time-efficient modes of exercise training. REHIT and HIIT have proven benefits but comparative effects of REHIT and HIIT in overweight and obese adults is yet to be determined.The significance of this study is to compare the effects of reduced exertion high intensity training (REHIT) versus high intensity interval training (HIIT) and will also investigate the effectiveness of REHIT as an alternative for overweight and obese individuals who perceive HIIT as too demanding. If found effective, it can also help in providing training protocol for optimizing cardiovascular health in this population, potentially leading to improved outcomes and reduced healthcare burdens. The results of this study will also add data to literature regarding the effects of REHIT and HIIT on anthropometric measures in overweight and obese. Main objective of this study is to compare the effects of reduced exertion high intensity training (REHIT) versus HIIT on anthropometric measures (weight, waist circumference, hip circumference, waist-to-hip ratio), CUN-BAE adiposity index and Cardiorespiratory fitness in overweight and obese individuals. The participants meeting the eligibility criteria will be recruited followed by random allocation to one of the 2 groups, following which they will be required to complete a self-reported demographic form and will be screened using Physical Activity Readiness Questionnaire (PAR-Q). Baseline evaluation will be done using tape measure for anthropometric, assessment of waist circumference and hip circumference, CUN-BAE index for adiposity and Queen's College step test for cardio-respiratory fitness. Experimental group A will perform REHIT while experimental group B will perform HIIT. Participants will also be provided with dietary restriction plan that will be followed during the training protocol. Exercise training would be performed for consecutive 6 weeks, 3 times a week on alternative days for total of 18 sessions.
The present invention relates to a compound capable of inhibiting PAR by forming a supramolecular structure with PAR, for use in inhibiting PAR or for use in treating or preventing a disease susceptible to PAR inhibition. The present invention further relates to a method of inhibiting PAR and a method of treating or preventing a disease susceptible to PAR inhibition, using a compound capable of inhibiting PAR by forming a supramolecular structure with PAR. Preferably the compound is dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof. The present invention also relates to a PAR inhibitor for use as a cardioprotective agent or for use in treating or preventing the cardiotoxic side effects of anthracyclines. The present invention further relates to a method of treating or preventing the cardiotoxic side effects of anthracyclines, using a PAR inhibitor. Furthermore, the present invention relates to a PAR inhibitor for use in treating or preventing extravasation. The present invention further relates to a method of treating or preventing extravasation, using a PAR inhibitor. Moreover, the present invention relates to a polymer of (i) polyadenylated RNA or DNA, and (ii) dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof, which may be used to treat or prevent a disease susceptible to PAR inhibition. Moreover, the present invention relates to a combination of a PAR inhibitor and a PARP inhibitor, or a combination of a PAR inhibitor and a second PAR inhibitor, which may be used to treat or prevent a disease susceptible to PAR inhibition. Lastly, the present invention relates to the use of dexrazoxane, levrazoxane, merbarone or mitindomide, or an analogue, derivative or metabolite thereof, for pre-treatment of mesenchymal stem cells.
The TIC-TOC efficacy trial is a multicenter, adaptive allocation, randomized controlled trial of children younger than 18 years with hemorrhagic injuries to the torso and/or brain to evaluate the efficacy of TXA on functional outcome as measured by the PedsQL. Children will be randomized to one of three arms: 1) TXA 15 mg/kg bolus over 30 minutes, followed by a 2 mg/kg/hr infusion over 8 hours), 2) TXA 30 mg/kg bolus over 30 minutes, followed by a 4 mg/kg/hr infusion over 8 hours), and 3) normal saline placebo. A third TXA dose (45 mg/kg bolus dose over 30 minutes, followed by a 6 mg/kg/hr infusion over 8 hours) may be added later in the trial if a dose effect based on accumulating data is noted. The trial will be conducted in the Pediatric Emergency Care Applied Research Network (PECARN) across 40 sites over 4 years of enrollment for a maximum sample size of 2000 patients.

A Bayesian adaptive randomization design will be used to evaluate the efficacy of TXA in children with hemorrhagic brain and/or torso injuries. Because different types of injury have different pathophysiology and potential response to TXA, three different injury strata will be evaluated: isolated hemorrhagic brain injury, isolated hemorrhagic torso injury, and both hemorrhagic brain and torso injuries. The efficacy of TXA will be analyzed across all enrolled children as well as across each type of injury.

The Bayesian adaptive trial design also efficiently evaluates the effectiveness of TXA across different TXA doses. The trial will randomize the first 500 patients to two doses of TXA and placebo at a fixed 1:1:1 ratio. Interim analyses will be conducted when 500, 750, 1000, 1250, 1500, and 1750 patients have been enrolled. At each interim analysis, randomization probabilities will be adjusted in order to preferentially allocate patients to better performing doses, while allocation to the placebo arm will stay fixed. The adaptive randomization will be based entirely on pre-planned rules using accumulating data. A Bayesian hierarchical model will be used to estimate the treatment effect for each of the injury types to be informed by the data accumulated from all injury types. At interim analyses, if a dose effect is noted towards the higher dose of TXA (30 mg/kg bolus then a 4 mg/kg/hr infusion) being more efficacious using pre-specified criteria, then a higher dose study arm (TXA 45 mg/kg bolus then a 6 mg/kg/hr infusion) will be opened later in the trial. If the dose response curve is flat, suggesting that TXA is ineffective, then futility stopping rules can end the trial early.
BACKGROUND: The molecular diversity exhibited by diffuse large B-cell lymphoma (DLBCL) is a significant obstacle facing current precision therapies. However, scoring using the International Prognostic Index (IPI) is inadequate when fully predicting the development of DLBCL. Reprogramming lipid metabolism is crucial for DLBCL carcinogenesis and expansion, while a predictive approach derived from lipid metabolism-associated genes (LMAGs) has not yet been recognized for DLBCL.
METHODS: Gene expression profiles of DLBCL were generated using the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. The LASSO Cox regression was used to construct an effective predictive risk-scoring model for DLBCL patients. The Kaplan-Meier survival assessment was employed to compare a given risk score with the IPI score and its impact on the survival of DLBCL patients. Functional enrichment examination was performed utilizing the KEGG pathway. After identifying hub genes via single-sample GSEA (ssGSEA), immunohistochemical staining and immunofluorescence were performed on lymph node samples from control and DLBCL patients to confirm these identified genes.
RESULTS: Sixteen lipid metabolism- and survival-associated genes were identified to construct a prognostic risk-scoring approach. This model demonstrated robust performance over various datasets and emerged as an autonomous risk factor for predicting the development of DLBCL patients. The risk score could significantly distinguish the development of DLBCL patients from the low-risk and elevated-risk IPI classes. Results from the inhibitory immune-related pathways and lower immune scores suggested an immunosuppressive phenotype within the elevated-risk group. Three hub genes, MECR, ARSK, and RAN, were identified to be negatively correlated with activated CD8 T cells and natural killer T cells in the elevated-risk score class. Ultimately, it was determined that these three genes were expressed by lymphoma cells but not by T cells in clinical samples from DLBCL patients.
CONCLUSION: The risk level model derived from 16 lipid metabolism-associated genes represents a prognostic biomarker for DLBCL that is novel, robust, and may have an immunosuppressive role. It can compensate for the limitations of the IPI score in predicting overall survival and has potential clinical application value.
Alzheimer's disease (AD) is a neurodegenerative disease that involves progressive cognitive decline accompanied by synaptic degeneration and impaired neurotransmission. Recent studies revealed that apple pomace, a waste byproduct of the apple processing industry, has beneficial health properties, but its potential to prevent and treat AD has not been determined. Herein, we examined the effects of apple pomace extract on N-methyl-D-aspartate receptor antagonist MK-801-induced memory impairment in mice. Repeated treatment with apple pomace extract for 7 days reversed the MK-801-induced impairment of associative memory and recognition memory. RNA sequencing revealed that repeated treatment with apple pomace extract altered the gene expression profile in the hippocampus of mice. Real-time PCR showed that apple pomace extract induced upregulation of the mRNA expression for Zfp125 and Gstp1. Furthermore, gene sets related to synapse and neurotransmission were upregulated by apple pomace extract. These findings indicate that apple pomace extract may be useful for the prevention and treatment of AD.
The subject invention concerns novel compositions for use in immunoassays, as well as immunoassays employing such novel compositions. The compositions comprise discrete charged colloidal particles comprised of small molecules which particles are capable of retaining their discrete character in an aqueous medium and composed of aggregates of lipophilic and/or amphiphilic organic molecules to which are bound non-covalently a label capable of producing a detectible signal and a ligand or an analog of the ligand capable of competing with a ligand for a ligand receptor. The discrete colloidal particle serves as a hub or nucleus for retaining the ligand or its analog and the label within a limited locus. The compositions are prepared by individually covalently bonding the ligand and the label, when not naturally lipophilic, to a lipophilic (includes amphiphilic) compound, normally a phospholipid. Depending upon the nature of the particle, the amphiphilic conjugated ligand and label are combined with the particle or alternatively may be combined with the compounds employed for preparing the particle under particle forming conditions. Particles are then obtained having the analog of the ligand and the label bound to the particle. The compositions find use in immunoassays where an interaction between the label and receptor provides a means for modulating a detectible signal. The interaction can be as a result of quenching or modification of fluorescence, where the label is a fluorescer, steric inhibition of the approach of a signal modifier to the label, such as a label receptor or with an enzyme label, an antienzyme or enzyme inhibitor, the inhibition of cleavage of an enzyme labile bond or the cooperative interaction of two labels, such as two enzymes, where the product of one enzyme is a substrate of another enzyme.
The utility model relates to a fetus soothing health care belt, which consists of a viscidity thread, an abutting belt, a connecting belt, a drug bag, an insulation layer and a surface layer. The whole body of the drug bag is in circular bag shape and is divided into three layers, wherein, the innermost layer comprises a cloth bag which is made of cotton cloth and filled with prescribed Chinese medicine; the insulation layer is coated outside the drug bag; and the surface layer is coated outside the insulation layer. The surface layer has the quality identical with that of the connecting belt and the abutting belt which are arranged at the two sides of the surface layer; the two ends of the connecting belt are respectively connected with a drug bag; the abutting belt is arranged at the other side of the drug bag corresponding to the connecting belt; and the outer end of the abutting belt is provided with the viscidity thread which is used for mutual abutting of the two abutting belts. The prescription of Chinese medicine used for soothing and enhancing the fetus comprises: 80 gram of gardenia, 80 gram of honeysuckle, 60 gram of angelica, 60 gram of radix paeoniae alba, 66 gram of hemlock parsley, 66 gram of rehmannia, 66 gram of radix scutellariae, 66 gram of cortex phellodendri and 6 gram of liquorice. The raw materials are crushed, divided into two parts, and filled into the cloth bags to form two drug bags which are the drug bags of the fetus soothing health care belt. The utility model has the advantages of simple overall structure, convenient use and easy promotion, facilitates the normal development of the fetus, and is beneficial to the health of the mother and the fetus.